Literature DB >> 29483112

Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.

Katarina Niward1,2, Linnea Ek Blom3,4, Lina Davies Forsman4,5, Judith Bruchfeld4,5, Erik Eliasson6, Thomas Schön7,8, Erja Chryssanthou3,9, Jakob Paues1,2.   

Abstract

The plasma tuberculosis drug activity (TDA) assay may be an alternative tool for therapeutic drug monitoring in resource-limited settings. In tuberculosis (TB) patients (n = 30), TDA and plasma levels of first-line drugs were analyzed 2 h postdose, 2 weeks after treatment initiation. Patients with plasma levels of rifampin lower than 8 mg/liter had a significantly lower median TDA (1.40 versus 1.68, P = 0.0013). TDA may be used to identify TB patients with suboptimal rifampin levels during TB treatment.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium tuberculosis; isoniazid; pharmacokinetics; rifampin

Mesh：

Substances：

Year:  2018        PMID： 29483112      PMCID： PMC5923115          DOI： 10.1128/AAC.00218-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Plasma drug activity assay for treatment optimization in tuberculosis patients.

Authors:  Scott K Heysell; Charles Mtabho; Stellah Mpagama; Solomon Mwaigwisya; Suporn Pholwat; Norah Ndusilo; Jean Gratz; Rob E Aarnoutse; Gibson S Kibiki; Eric R Houpt
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

2.  Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements.

Authors:  Marieke G G Sturkenboom; Mathieu S Bolhuis; Onno W Akkerman; Wiel C M de Lange; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Int J Tuberc Lung Dis       Date:  2016-12       Impact factor: 2.373

Review 3.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 4.  Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.

Authors:  Kyle John Wilby; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

Review 5.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Authors:  Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

7.  Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment.

Authors:  Giovanni Sotgiu; Jan-Willem C Alffenaar; Rosella Centis; Lia D'Ambrosio; Antonio Spanevello; Andrea Piana; Giovanni Battista Migliori
Journal:  Int J Infect Dis       Date:  2015-03       Impact factor: 3.623

8.  A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

Authors:  Martin J Boeree; Andreas H Diacon; Rodney Dawson; Kim Narunsky; Jeannine du Bois; Amour Venter; Patrick P J Phillips; Stephen H Gillespie; Timothy D McHugh; Michael Hoelscher; Norbert Heinrich; Sunita Rehal; Dick van Soolingen; Jakko van Ingen; Cecile Magis-Escurra; David Burger; Georgette Plemper van Balen; Rob E Aarnoutse
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 21.405

Review 9.  Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Marlanka A Zuur; Mathieu S Bolhuis; Richard Anthony; Alice den Hertog; Tridia van der Laan; Bob Wilffert; Wiel de Lange; Dick van Soolingen; Jan-Willem C Alffenaar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-03-24       Impact factor: 4.481

10.  High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Authors:  Martin J Boeree; Norbert Heinrich; Rob Aarnoutse; Andreas H Diacon; Rodney Dawson; Sunita Rehal; Gibson S Kibiki; Gavin Churchyard; Ian Sanne; Nyanda E Ntinginya; Lilian T Minja; Robert D Hunt; Salome Charalambous; Madeleine Hanekom; Hadija H Semvua; Stellah G Mpagama; Christina Manyama; Bariki Mtafya; Klaus Reither; Robert S Wallis; Amour Venter; Kim Narunsky; Anka Mekota; Sonja Henne; Angela Colbers; Georgette Plemper van Balen; Stephen H Gillespie; Patrick P J Phillips; Michael Hoelscher
Journal:  Lancet Infect Dis       Date:  2016-10-26       Impact factor: 25.071
View more
  2 in total

Review 1.  Nanotechnology as a tool to overcome the bariatric surgery malabsorption.

Authors:  Osaid Almeanazel; Fars Alanazi; Ibrahim Alsarra; Doaa Alshora; Faiyaz Shakeel; Ahmad Almnaizel; Mohammed Alahmed; Ehab Fouad
Journal:  Saudi Pharm J       Date:  2020-03-19       Impact factor: 4.330

2.  Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis.

Authors:  Bibie N Said; Scott K Heysell; Getnet Yimer; Rob E Aarnoutse; Gibson S Kibiki; Stellah Mpagama; Peter M Mbelele
Journal:  Int J Mycobacteriol       Date:  2021 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.